Trials / Unknown
UnknownNCT03279614
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Phase II Study of SOX as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Currently, there is no standard second line treatment for patients with neuroendocrine carcinoma. SOX regimen has shown promising in previous study. The study was designed to confirm thet SOX regimen can be used as a second-line regimen for patients with advanced or metastatic neuroendocrine carcinoma who have progressed after first-line chemotherapy with platinum based regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOX | OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2019-09-01
- Completion
- 2020-09-01
- First posted
- 2017-09-12
- Last updated
- 2017-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03279614. Inclusion in this directory is not an endorsement.